Rigel Pharmaceuticals, Inc. (RIGL) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-03
How it makes money
It earns revenue by selling specialized oral therapies for hematologic disorders and cancer, with sales growth driven by higher volume, increased prices, and new product launches.
It commercializes FDA-approved pharmaceutical products including TAVALISSE for chronic immune thrombocytopenia, REZLIDHIA for acute myeloid leukemia, and GAVRETO for non-small cell lung and thyroid cancers. Earnings depend directly on net product sales recognized when customers obtain control of the product upon delivery.
Revenue growth is propelled by increased quantities sold, higher prices per bottle, and expanded commercialization efforts. For instance, TAVALISSE net product sales reached $158.8 million in 2025, marking a 51.6% increase compared to $104.8 million in 2024, driven primarily by higher volume, a lower revenue reserves rate, and price increases.
What protects it: the moat
It relies on regulatory approvals and exclusive license or asset purchase agreements to protect its commercialized specialty therapies from direct generic competition.
Management asserts that regulatory designations, such as being the only approved oral SYK inhibitor for chronic ITP or holding exclusive worldwide and US rights acquired through agreements with companies like Forma and Blueprint, safeguard its market position. However, the filing discloses that these protections depend heavily on maintaining valid intellectual property, successfully navigating regulatory frameworks, and correctly estimating underserved patient populations without guaranteeing that competitors will not develop alternative therapies or that market opportunities will meet projections.
What growth costs
It must continually reinvest in clinical trials, research and development, sales force expansion, and drug candidate acquisitions to sustain and grow its pipeline.
Maintaining and expanding the business requires substantial financial and human resources dedicated to clinical development programs, such as the Phase 1b study for R289 in lower-risk MDS. The company must also support the training and ongoing activities of its sales force, integrate acquired product lines, and fund internal drug discovery efforts. Furthermore, expanding the organization to manage commercial activities introduces significant operational overhead and administrative costs.
What could damage it
Inaccurate patient population estimates or clinical trial failures could permanently impair earnings by destroying the commercial viability of key product candidates.
If the actual prevalence of underserved diseases or the subset of patients seeking treatment is smaller than projected, expected revenues will fall short. Concurrently, if ongoing or future clinical trials reveal inadequate efficacy or harmful side effects, development efforts will fail, eroding the pipeline value that underpins future growth.
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.